Thermo Fisher Scientific and Immundiagnostik announce collaboration

Thermo Fisher Scientific will be partnering Immundiagnostik to develop new commercial assays for use in research and routine clinical analysis.

The collaboration will involve the creation of novel mass spectrometry-based assays for qualitative and quantitative analysis of proteins and peptides, with a specific focus on advancing biomarker research.

Utilising Immundiagnostik's ImmunoTube antibody technology and Thermo Fisher's liquid chromatography-triple quadrupole mass spectrometry (LC-MS/MS) analytics, the partners will produce diagnostic tests for cardiovascular diseases and bone metabolism disorders.

As part of the collaboration, Immundiagnostik will also be providing a venue for demonstrating various Thermo Fisher technology applications.

Jeff Zonderman, Thermo Fisher's director of clinical and toxicology LC/MS, said: "We are impressed with Immundiagnostik's antibody expertise and are confident that the immunoaffinity-purification of proteins will take quantitative LC-MS/MS protein analysis to the next level."

This comes after the company completed the acquisition of leading transplant diagnostics specialist One Lambda last month in a deal worth $182 million (113.61 million pounds).